the prostate cancer therapeutics market forecast 2014 2024

The Prostate Cancer Therapeutics Market Forecast 2014-2024Opportunities for Leading Companies

©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

www.visiongain.com

Contents

1.1 The Prostate Cancer Therapeutics Market Overview

1.2 Prostate Cancer Therapeutics Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who is This Report For?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Reports

1.10 About Visiongain

2.1 What is Cancer?

2.2 Phenotypic Characteristics of Cancer Cells

2.2.1 Uncontrollable Growth

2.2.2 Loss of Apoptosis Pathways

2.2.3 Lack Differentiation

2.2.4 Increased Angiogenesis

2.2.5 Potential for Metastasis

2.2.6 Genetic Instability

2.3 What Causes Cancer?

2.4 Worldwide Prevalence of Cancer: A Global Picture

2.5 What is Prostate Cancer?

2.6 Worldwide Prevalence of Prostate Cancer: Rapid Global Growth

2.7 Risk Factors for Prostate Cancer

2.8 How is Prostate Cancer Diagnosed?

1. Report Overview

2. Introduction to Prostate Cancer

www.visiongain.com

Contents 2.8.1 PSA Testing

2.8.2 Digital Rectal Examination Testing

2.8.3 Prostate Cancer Screening: Beneficial or Costly?

2.8.4 Newly Approved Tests May Improve Diagnosis

2.8.4.1 Prostate Cancer Diagnostics in the Pipeline

2.9 Treatment Sequence for Prostate Cancer

2.9.1 Localised Prostate Cancer: Surgery/Radiation is Most Preferred

2.9.1.1 Brachytherapy

2.9.1.2 Radical Prostatectomy

2.9.1.3 External Beam Radiation Therapy

2.9.1.4 Cryotherapy

2.9.1.5 High-Intensity Focussed Ultrasound (HIFU)

2.9.2 Advanced Local or Metastatic Prostate Cancer: Androgen Deprivation Therapy

2.9.3 Non-Metastatic CRPC: Ketoconazole and Anti-Androgens

2.9.4 Metastatic CRPC: Expanding the Standard Taxotere Treatment Paradigm

2.9.5 First Line Chemotherapy: Docetaxel is a Standard Treatment

2.9.6 Post Docetaxel Therapy: Five FDA Approved Drugs

2.9.7 Second Line Chemotherapy: Jevtana Approved in 2010

3.1 The Global Prostate Cancer Therapeutics Market, 2013

3.2 The Global Prostate Cancer Therapeutics Market Forecast, 2014-2024

3.3 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints, 2014-2024

4.1 The Prostate Cancer Drugs Market: Increasing Choice of Drugs will Mean Higher

Competition

4. The Prostate Cancer Drugs Market 2014-2024

3. The Prostate Cancer Therapeutics Market 2014-2024

www.visiongain.com

Contents 4.2 The Prostate Cancer Drugs Market, 2013

4.3 Leading Prostate Cancer Drugs: Market Forecast, 2014-2024

4.3.1 The Market Shares of Leading Prostate Cancer Drugs, 2014-2024

4.4 First Generation Chemotherapies

4.4.1 Taxotere (Sanofi)

4.4.1.1 Taxotere Sales, 2013

4.4.1.2 Taxotere Sales Forecast, 2014-2024

4.5 Second Generation Chemotherapies

4.5.1 Jevtana (Sanofi)

4.5.1.1 Jevtana Sales, 2013

4.5.1.2 Jevtana Sales Forecast, 2014-2024

4.6 First Generation Hormones

4.6.1 Casodex (AstraZeneca)

4.6.1.1 Casodex Sales, 2013

4.6.1.2 Casodex Sales Forecast, 2014-2024

4.6.2 Lupron (AbbVie)

4.6.2.1 Lupron Sales, 2013

4.6.2.2 Lupron Sales Forecast, 2014-2024

4.6.3 Zoladex (AstraZeneca)

4.6.3.1 Zoladex Sales, 2013

4.6.3.2 Zoladex Sales Forecast, 2014-2024

4.7 Second Generation Hormones

4.7.1 Zytiga (Johnson & Johnson)

4.7.1.1 Zytiga Sales, 2013

4.7.1.2 Zytiga Sales Forecast, 2014-2024

4.7.2 Xtandi (Medivation/ Astellas Pharma)

4.7.2.1 Xtandi Sales, 2013

4.7.2.2 Xtandi Sales Forecast, 2014-2024

4.8 Immunotherapies

www.visiongain.com

Contents 4.8.1 Provenge (Dendreon Corporation)

4.8.1.1 Provenge Sales, 2013

4.8.1.2 Provenge Sales Forecasts, 2014-2024

4.9 Radiopharmaceuticals

4.9.1 Xofigo (Bayer)

4.9.1.1 Xofigo Sales, 2013

4.9.1.2 Xofigo Sales Forecast, 2014-2024

4.10 Other Drugs

4.11 Prostate Cancer Drugs Pipeline, 2014

4.11.1 Phase III Development

4.11.1.1 DCVax-Prostate (NorthWest Biotherapeutics)

4.11.1.2 Tookad Soluble (Steba Biotech)

4.11.1.3 ProstAtak (Advantagene)

4.11.1.4 Tasquinimod (Active biotech AB/Ipsen)

4.11.1.5 Custirsen (Oncogenex/ Teva)

4.11.1.6 Cabozantinib (Exelixis)

4.11.1.7 Prostvac (Bavarian Nordic)

4.11.2 Failed Phase III Drugs

4.11.2.1 Custirsen (OncoGenex)

4.11.2.2 Yervoy (Bristol Myers Squibb)

4.11.2.3 Orteronel (Millenium Pharmaceuticals)

4.11.3 Phase II development

4.11.3.1 GDC-0980 (Roche)

4.11.3.2 GDC-0068 (Roche)

4.11.3.3 PSMA ADC (Progenics Pharmaceuticals)

4.11.3.4 Galeterone (Tokai Pharmaceuticals)

4.11.3.5 OGX-427 (OncoGenex Pharmaceuticals)

4.11.3.6 ARN-509 (Johnson & Johnson)

4.11.3.7 Abituzumab (Dl7E6) (Merck)

4.11.3.8 Ipilimumab (Yervoy) (Bristol Myers Squibb)

www.visiongain.com

Contents 4.11.4 Phase I

4.11.4.1 ASG-5ME (Agensys/Seattle Genetics)

4.11.4.2 EMD-525797 (EMD Serono)

4.11.4.3 MGAH22 (MacroGenics)

4.11.4.4 RG7450 (Roche)

4.11.4.5 BAY2010112 (Bayer Pharmaceuticals)

4.11.4.6 BX-201 (Bellicum Pharmaceuticals)

4.12 The Leading Companies in the Prostate Cancer Drugs Market, 2014

4.12.1 Johnson & Johnson (J&J)

4.12.1.1 Sales and Performance Analysis, 2013

4.12.1.2 Pharmaceutical Segment Sales Analysis, 2013

4.12.1.3 Oncology Drugs Sales and Performance Analysis, 2013

4.12.1.4 Pharmaceutical Segment R&D Performance Analysis, 2013

4.12.1.5 Recent M&A Activity

4.12.1.5.1 Acquisition of Aragon Pharmaceuticals

4.12.2 AstraZeneca


4.12.2.2 Pharmaceutical Segment Sales Analysis by Segment, 2013

4.12.2.3 Oncology Drugs Sales and Performance Analysis, 2013

4.12.2.4 R&D Performance Analysis, 2013

4.12.3 Sanofi


4.12.3.2 Sales and Performance Analysis by Segment, 2012

4.12.3.3 Oncology Sales and Performance Analysis, 2013


4.12.3.5 Oncology Pipeline Portfolio

4.12.4 AbbVie



4.12.4.3 Oncology Portfolio Pipeline Products, 2013

www.visiongain.com

Contents

5.1 The Prostate Cancer Devices Market 2013

5.2 The Prostate Cancer Devices Market Forecast, 2014-2024

5.2.1 The Market Shares of Leading Prostate Cancer Devices Submarkets, 2014-2024

5.3 The Brachytherapy Market, 2014-2024

5.4 The Radical Prostatectomy Market 2014-2024

5.4.1 Intuitive Surgical’s da Vinci Surgical System will Drive Market Growth

5.5 The External Beam Radiation Therapy Market, 2014-2024

5.6 The HIFU Market, 2014-2024

5.7 The Cryotherapy Market, 2014-2024

5.8 Leading Companies in the Prostate Cancer Devices Market 2014-2024

5.8.1 Varian Medical Systems


5.8.1.2 Oncology Segment Sales Analysis, 2013

5.8.1.3 Sales Analysis by Region, 2013


5.8.1.5 Key Oncology Products, 2013

5.8.1.6 Varian and Siemens Partnership: Shaping the Future of Cancer Care

5.8.2 Elekta


5.8.2.2 Sales and Performance Analysis by Region, 2012

5.8.2.3 Elekta and Philips Establish Research Consortium

5.8.2.4 Product Launch and Development, 2013

5.8.3 Theragenics Corporation (acquired by Juniper)

5.8.3.1 Theragenics Sales Performance Analysis, 2012

5.8.3.2 Theragenics Sales Performance by Operation, 2012

5.8.3.3 Theragenics sales and Performance Analysis by Business Unit, 2012

5.8.3.4 Mergers and Acquisitions

5. The Prostate Cancer Devices Market 2014-2024

www.visiongain.com

Contents 5.8.3.4.1 Juniper’s acquisition of Theragenics

5.8.3.4.2 Acquisition of Needle Tech Products

5.8.3.4.3 Acquisition of Galt Medical

5.8.3.4.4 Acquisition of CP Medical

6.1 Regional Breakdown of the Prostate Cancer Therapeutics Market, 2013

6.2 The Prostate Cancer Therapeutics Market: Regional Forecast, 2014-2024

6.2.1 Market Shares Forecasts of Leading National Prostate Cancer Therapeutics

Markets, 2014-2024

6.3 The US Prostate Cancer Therapeutics Market 2014-2024: Largest National Market

6.4 The European Prostate Cancer Therapeutics Market, 2013

6.4.1 The European Prostate Cancer Therapeutics Market, 2014-2024

6.4.1.1 The German Prostate Cancer Therapeutics Market, 2014-2024

6.4.1.2 The French Prostate Cancer Therapeutics Market, 2014-2024

6.4.1.3 The UK Prostate Cancer Therapeutics Market, 2014-2024

6.4.1.4 The Spanish Prostate Cancer Therapeutics Market, 2014-2024

6.4.1.5 The Italian Prostate Cancer Therapeutics Market, 2014-2024

6.5 The Japanese Prostate Cancer Therapeutics Market, 2014-2024

6.6 The Brazilian Prostate Cancer Therapeutics Market, 2014-2024

6.7 The Russian Prostate Cancer Therapeutics Market, 2014-2024

6.8 The Indian Prostate Cancer Therapeutics Market, 2014-2024

6.9 The Chinese Prostate Cancer Therapeutics Market, 2014-2024

6.10 The South Korean Prostate Cancer Therapeutics Market, 2014-2024

6.11 The Mexican Prostate Cancer Therapeutics Market, 2014-2024

6.12 The Rest of the World Prostate Cancer Therapeutics Market, 2014-2024

6. The Leading National Markets 2014-2024

www.visiongain.com

Contents

7.1 SWOT Analysis, 2014-2024

7.2 Strengths

7.2.1 Prostate Cancer is a High Profile Disease

7.2.2 Rapidly Expanding Ageing Population

7.2.3 Targeted Therapies can Command Premium Prices

7.2.4 Strong R&D Pipeline

7.2.5 Successful Launches through Partnerships between Small/Big Pharma Companies

7.2.6 Use of Off-label Drugs is Common

7.3 Weaknesses

7.3.1 Prostate Cancer Drugs are Expensive

7.3.2 R&D Failures in Late-stage Development

7.3.3 Controversy Over the Value of New Prostate Cancer Devices

7.3.4 U.S Medical Excise Tax

7.4 Opportunities

7.4.1 Rising Incidence of cancer

7.4.2 Emerging National Markets will Drive Growth

7.4.3 Stem Cells Offer Promise

7.4.4 Advances in Diagnostic Technologies: CTC as a Biomarker

7.5 Threats

7.5.1 Concerns about Efficacy and Toxicity of Drugs

7.5.2 Who will Pay for the High Cost of Drugs and Devices?

7.5.3 Governments Decreasing Healthcare Spending

7.5.4 Increase in Generic Competition

7.5.5 Increase in the Practice of 'Active Surveillance'

7.6 Porter’s Five Force Analysis

7.6.1 Rivalry Among Competitors [High]

7.6.2 Threat of New Entrants [High]

7. Qualitative Analysis of the Prostate Cancer Therapeutics Market

2014-2024

www.visiongain.com

Contents 7.6.3 Power of Suppliers [Low]

7.6.4 Power of Buyers [High]

7.6.5 Threat of Substitutes [Low]

8.1 Professor Malcolm Mason, Cancer Research UK's Prostate Cancer Expert

8.1.1 Factors Affecting the Growth of Prostate Cancer

8.1.2 Prostate Cancer: To Treat or Not to Treat?

8.1.3 Alternatives to PSA Testing

8.1.4 A Common Option for Early Stage Prostate Cancer: Radical Prostatectomy

8.1.5 Large Number of Clinical Trials Studying Prostate Cancer

8.1.6 Combination Therapy: Better Survival Rates

8.1.7 Novel Prostate Cancer Drugs: A Question of Cost

8.2 Interview with Hans Kolam, Chief Financial Officer and Helen Tuvesson, Chief Scientific

Officer, Active Biotech

8.2.1 Tasquinimod: Phase III Pre-Chemotherapy Study

8.2.2 Tasquinimod: An Innovative Mode of Prostate Cancer Treatment

8.2.3 Active Biotech/Ipsen: Partnerships are Pivotal for Oncology Drug Development

8.2.4 Tasquinimod: Other Indications in the Pipeline

8.2.5 Competitive Landscape of the Prostate Cancer Drugs Market

8.2.6 The Drivers of Growth in the Prostate Market

8.3 Dr. Estuardo Aguilar-Cordova, Co-founder, CEO and Chairman, Advantagene

8.3.1 ProstAtak’s Mechanism for Prostate Cancer Prevention

8.3.2 ProsAtak’s Market Size

8.3.3 Immunotherapy: The Future for Cancer Treatment

8.3.4 Active Surveillance: A growing Trend

8. Expert Opinions

www.visiongain.com

Contents #

9.1 The Prostate Cancer Therapeutics Market, 2014-2024

9.2 The US Will Remain the Largest National Market from 2014 to 2024

9.3 Concluding Remarks

9. Conclusions

www.visiongain.com

The Prostate Cancer Therapeutics Market Forecast 2014-2024: Opportunities for Leading Companies

4.6.2.2Lupron Sales Forecast, 2014-2024 Lupron sales have fallen over the years due to strong generic competition. We do not expect a

complete erosion of Lupron’s market share primarily owing to its current market dominance and we

expect it will to continue having significant brand recognition in the future. The sales will drop from

$550.00m in 2013 to $449.01m in 2018, visiongain expects a further fall in the second half of the

forecast period for Lupron, dropping to $297.65m by 2024. The CAGR for the period 2013-2018

and 2018-2024 is expected to be -4.0% and -6.6% respectively. Lupron’s market share of the

prostate cancer drugs market will decline from 11.0% in 2013 to 2.6% in 2024.

Table 4.8 AbbVie: Lupron Revenue Forecast ($m), AGR (%), CAGR(%), 2013-2024 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

Lupron ($m) 550.00 538.45 523.37 505.06 483.84 449.01 407.25 366.12 330.97 314.09 304.04 297.65

AGR (%) -2.1 -2.8 -3.5 -4.2 -7.2 -9.3 -10.1 -9.6 -5.1 -3.2 -2.1

CAGR (%) 2013-2018

CAGR (%) 2013-2024 -5.4

-4.0 2018-2024 -6.6

Figure 4.9 AbbVie: Lupron Revenue Forecast ($m), AGR (%) 2013-2024

-12.0

-10.0

-8.0

-6.0

-4.0

-2.0

0.0

0

100

200

300

400

500

600

AG

R (

%)

Rev

enu

e ($

m)

Year

Revenue ($m) AGR (%)

Source: visiongain 2014

Source: visiongain 2014

www.visiongain.com


4.12.2.3 Oncology Drugs Sales and Performance Analysis, 2013 The leading product in its Oncology portfolio is Zoladex (goserelin), which achieved sales of $996m

in 2013; it is the only oncology drugs in AstraZeneca’s portfolio that has generated sales close to

$1bn. It contributed 31.2% of the total oncology revenues. Zoladex (goserelin) is used for the

breast and prostate cancer indication. Zoladex and Casodex are the leading endocrine therapies

for the treatment of prostate cancer. However, the oncology segment revenue declined by 9.3%

between 2012 and 2013, owing to generic competition to their leading oncology franchises such as

Casodex and Arimidex.

Figure 4.25 AstraZeneca: Oncology Drugs Revenue Share (%) by Brand Product, 2013

Table 4.26 AstraZeneca: Oncology Drugs Revenue ($m), Change in Revenue (%) and Revenue Shares (%),2012-2013

Drug Revenue ($m) 2012 Revenue ($bn) 2013 Change in Revenue (%) Revenue Shares 2013 (%)

Zoladex 1093 996 -9.7 31.2Faslodex 654 681 4.0 21.3Iressa 611 647 5.6 20.3Arimidex 543 351 -54.7 11.0Casodex 454 376 -20.7 11.8Others 134 142 5.6 4.4Total 3489 3193 -9.3 100.0

Zoladex 31.2%

Faslodex 21.3%

Iressa 20.3%

Arimidex 11.0%

Casodex 11.8%

Others 4.4%

Source: AstraZeneca 2014; Visiongain 2014

Source: AstraZeneca 2014; Visiongain 2014

www.visiongain.com


A major driver for cryosurgery is the fact that it is less invasive than radical prostatectomy, so there

is usually less blood loss, a shorter hospital stay, shorter recovery period, and less pain than with

surgery. A constraint for the adoption of the therapy at this time is that compared with surgery or

radiation therapy, doctors know much less about the long-term effectiveness of cryosurgery.

Table 5.8 The Cryotherapy Therapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2024

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

Cryotherapy ($m) 102.00 112.00 123.31 136.13 150.56 167.88 188.86 209.45 230.81 253.43 277.25 303.04

AGR (%) 9.8 10.1 10.4 10.6 11.5 12.5 10.9 10.2 9.8 9.4 9.3

CAGR (%) 2013-2018

CAGR (%) 2013-2024 10.4

10.5 2018-2024 10.3

Figure 5.10 The Cryotherapy Therapy Market Forecast: Revenue ($m), AGR (%), 2014-2024

0.0

2.0

4.0

6.0

8.0

10.0

12.0

14.0

0

50

100

150

200

250

300

350

AG

R (

%)

Rev

enu

e ($

m)

Year

Revenue ($m) AGR (%)

Source: Visiongain 2014

Source: Visiongain 2014

the prostate cancer therapeutics market forecast 2014 2024

Business

bristol myers squibb

lupron revenue forecast

prostate cancer

prostate cancer 2

leading companies

leading companies 4

market shares

generation chemotherapies 4